New Diabetes Drug would help Lose Weight & Control Blood Pressure
A British scientist claims to have discovered a new diabetes treatment using a drug in the SGLT 2 inhibitor class. The proposed name of this diabetes medication is Dapagliflozin, and development of this new drug is a combined effort of two pharmaceutical giants AstraZeneca and Bristol Myers Squib.
Dr Clifford Bailey, head of the research team and professor for clinical science at Aston, claims that the drug helps control diabetes in a completely new way. Dapagliflozin, currently under trial, is believed to work by increasing elimination of blood sugar levels through urination.
The drug is, Dr Clifford says, multipurpose, as it can also be used for the treatment of other diseases. Unlike other diabetes medications (for example, Avandia and Actos), usage of Dapagliflozin will not be limited to specific stages of diabetes. Also, it is believed that the drug is safe to use for longer periods of time when compared to other diabetes medications.
Obesity is considered to be an indication of diabetes type 2, and losing weight is recommended to keep blood sugar levels down. Clinical trial results showed patients taking Dapagliflozin lost 4-7 pounds. This is quite significant as it will also help to control blood pressure, as well as heart disease, which result from being overweight.
Dapagliflozin is a once-a-day diabetes drug. Now, along with Bydureon, Dapagliflozin is in the group of diabetes drugs that are eagerly awaited by diabetes patients across the world.